Intra-Cellular Therapies, Inc. (ITCI)
- Previous Close
74.01 - Open
73.71 - Bid 73.00 x 200
- Ask 73.11 x 100
- Day's Range
72.41 - 74.11 - 52 Week Range
45.50 - 84.89 - Volume
713,985 - Avg. Volume
969,353 - Market Cap (intraday)
7.628B - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
-- - EPS (TTM)
-1.46 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
91.91
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
www.intracellulartherapies.com610
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ITCI
Performance Overview: ITCI
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ITCI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ITCI
Valuation Measures
Market Cap
7.63B
Enterprise Value
7.15B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.17
Price/Book (mrq)
12.90
Enterprise Value/Revenue
15.46
Enterprise Value/EBITDA
-44.99
Financial Highlights
Profitability and Income Statement
Profit Margin
-30.08%
Return on Assets (ttm)
-13.43%
Return on Equity (ttm)
-22.39%
Revenue (ttm)
464.37M
Net Income Avi to Common (ttm)
-139.67M
Diluted EPS (ttm)
-1.46
Balance Sheet and Cash Flow
Total Cash (mrq)
497.94M
Total Debt/Equity (mrq)
2.86%
Levered Free Cash Flow (ttm)
-28.97M